| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |